Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of High Dose Interferon Alfa 2-b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma

NCT00006237 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00006237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of High Dose Interferon Alfa 2-b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2000
Completion date
July 31, 2012
Enrollment
432 (actual)
Sites
297

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)